Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a simple referral to palliative care ease End-of-Life suffering for cancer patients?

NCT ID NCT06150027

Symptom relief Sponsor: Centre Leon Berard Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether cancer patients who visit the emergency room for urgent problems benefit from being immediately referred to a palliative care team. The goal is to see if this reduces aggressive treatments and hospitalizations in the last month of life. The trial involves 240 adults with incurable cancer at French cancer centers.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
systematic referral to a palliative care team
What this could lead to
If successful, this could show that early palliative care referral reduces unnecessary hospitalizations and aggressive treatments near the end of life for cancer patients.
What could go wrong
This is a relatively small study (240 patients) and results may not apply to all cancer centers. The intervention is a referral process, not a drug, so benefits may be modest.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 240 people

The number the study aims to enrol. It can still change while the study runs.

Started

Sep 2024

Expected to finish

Aug 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Male or female ≥ 18 years at the day of consenting to the study; * Confirmed diagnosis of any type of solid or haematology tumours, with or without Current oncological treatment, such as chemotherapy, immunotherapy, targeted therapy, etc; * Unscheduled admission in a French Regional Comprehensive Anti-Cancer Centre due to an acute, unpredictable, intercurrent event related to cancer, its therapies or a comorbidity; * Patient for whom disease is considered as not curable; * PALLIA-10 Score \> 3/10; * Willingness and ability to comply with the study requirements; * Signed and dated informed consent indicating that the patient has been informed of all the aspects of the trial prior to enrolment; * Patient must be covered by a medical insurance. Exclusion Criteria: * Patient without consciousness, unable to provide a written informed consent (context of emergency); * Patient treated with a curative intent; * Previous randomization in this clinical study; * Patients already followed-up by a palliative care team; * Life expectancy shorter than 1 month, as per the emergency units' staff judgement. * Any medical or psychosocial condition that would compromise the patient's compliance to the study visits or would likely interfere with the completion of Patient-Reported Outcomes. * Patients under tutorship or curatorship.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cancer Emergencies neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cancer Emergencies

Contacts and locations

Locations

  • Centre Léon Bérard

    Lyon, 69008, France

  • ICM Val d'Aurelle

    Montpellier, 34090, France

  • Institut Curie - Paris

    Paris, 75005, France

  • Institut Curie - Saint Cloud

    Saint-Cloud, 92210, France

  • Institut Gustave Roussy

    Villejuif, 94805, France

  • Institut de Cancérologie de Lorraine

    Vandœuvre-lès-Nancy, 54519, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.